News & Updates

Individuals with nonalcoholic fatty liver disease (NAFLD) may face stigma from the disease or comorbidities, but the perceptions of shame differ across patients, healthcare providers, geographic locations, and subspecialties, reveals a study.

A study has found the high bilirubin, pretreatment hypoalbuminemia, and biochemical tests indicative of hepatic or renal dysfunctions are independently associated with short-term mortality in patients with advanced hepatocellular cancer (HCC) receiving atezolizumab and bevacizumab (Atezo/Bev).

Dietary niacin intake may benefit individuals with nonalcoholic fatty liver disease (NAFLD), with a study suggesting that a higher intake lowers the risk of mortality.